Therefore, lower amounts of DNMT3A protein might reduce enzymatic activities in AML patients with DNMT3A mutations, which regulate crucial gene expression in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells. This evidence concerns the gene BCS1L and acute myeloid leukemia.